FDA Inspection 1161837 — Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc. — FEI 3012279857

The FDA completed an inspection of Hikma Pharmaceuticals USA Inc. on Feb 7, 2022 in Bedford, OH. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 1 citation was issued during this inspection. Product area: Drugs.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Feb 7, 2022
Fiscal Year
2022
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Bedford, OH (United States)

Citations

IDCFRDescription
110521 CFR 211.22(d)Procedures not in writing, fully followed

Need the full FDA record for Hikma Pharmaceuticals USA Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.